Drug Description in Trials / DrugBank / KEGG DRUG
Search results
Showing 1 to 8 of 8 descriptions
No. | 薬物名(臨床試験情報から抽出) | DrugBank | KEGG DRUG | KEGG GENES | KEGG PATHWAY | 指定難病告示番号 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Anti-von Willebrand Factor Nanobody, Caplacizumab (Cablivi (TN)) | 2件: Caplacizumab Caplacizumab (Cablivi),Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| 1件: VWF VWF 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬1. Anti-von Willebrand Factor Nanobody, Caplacizumab
| ||||||||||||||
2 | Anti-von Willebrand Factor Nanobody, INN = Caplacizumab (Cablivi (TN)) | 2件: Caplacizumab Caplacizumab (Cablivi),Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| 1件: VWF VWF 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬2. Anti-von Willebrand Factor Nanobody, INN = Caplacizumab
| ||||||||||||||
3 | CABLIVI | 1件: Caplacizumab Caplacizumab (Cablivi) | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬3. CABLIVI
| 1件: VWF VWF 💬3. CABLIVI
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬3. CABLIVI
| ||||||||||||||
4 | Cablivi® | 1件: Caplacizumab Caplacizumab (Cablivi) | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬4. Cablivi®
| 1件: VWF VWF 💬4. Cablivi®
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬4. Cablivi®
| ||||||||||||||
5 | CAPLACIZUMAB (Cablivi (TN)) | 1件: Caplacizumab Caplacizumab (Cablivi) | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬5. CAPLACIZUMAB
| 1件: VWF VWF 💬5. CAPLACIZUMAB
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬5. CAPLACIZUMAB
| ||||||||||||||
6 | Caplacizumab (ALX-0081) (Cablivi (TN)) | 1件: Caplacizumab Caplacizumab (Cablivi) | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬6. Caplacizumab (ALX-0081)
| 1件: VWF VWF 💬6. Caplacizumab (ALX-0081)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬6. Caplacizumab (ALX-0081)
| ||||||||||||||
7 | Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081) (Cablivi (TN)) | 2件: Caplacizumab Caplacizumab (Cablivi),Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬7. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| 1件: VWF VWF 💬7. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬7. Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081)
| ||||||||||||||
8 | Caplacizumab (an anti-von Willebrand Factor Nanobody) (Cablivi (TN)) | 2件: Caplacizumab Caplacizumab (Cablivi),Von Willebrand factor human | 1件: Caplacizumab
Caplacizumab
(Cablivi (TN)) 💬8. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| 1件: VWF VWF 💬8. Caplacizumab (an anti-von Willebrand Factor Nanobody)
| 8件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, F ... | 1件: 64 64 💬8. Caplacizumab (an anti-von Willebrand Factor Nanobody)
|